Somerville, MA, United States of America

Linda R Gritz

USPTO Granted Patents = 19 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 1)

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 196(Granted Patents)

Location History:

Sommerville, MA (US) (1997)
Somerville, MA (US) (1993 - 2015)

Company Filing History:

9 out of 15

Therion Biologics Corporation

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

4. 1 out of 1

Theriod Biologics, Incorporated

patent

5. 1 out of 1,207

Dana-farber-cancer Institute Inc.

patents

where one patent can have more than one assignee

Years Active: 1993-2015

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8933041 - System for treating and preventing breast cancer (2015-01-13),

2. 8911991 - Multi-antigen vectors of melanoma (2014-12-16),

3. 8901093 - Custom vectors for treating and preventing pancreatic cancer (2014-12-02),

4. 8562970 - Modified CEA/B7 vector (2013-10-22),

5. 8530442 - Modified CEA nucleic acid and expression vectors (2013-09-10),

6. 8236776 - Modified CEA nucleic acid and expression vectors (2012-08-07),

7. 7786278 - Modified CEA nucleic acid and expression vectors (2010-08-31),

8. 7638134 - Insertion sites in fowlpox vectors (2009-12-29),

9. 7410644 - Recombinant pox virus for immunization against tumor-associated antigens (2008-08-12),

10. 7118738 - Recombinant pox virus for immunization against MUC1 tumor-associated antigen (2006-10-10),

11. 6051410 - Self-assembled, defective, nonself-propagating viral particles (2000-04-18),

12. 5804196 - Self assembled, defective, nonself-propagating viral particles (1998-09-08),

13. 5747324 - Self-assembled, defective, non-self-propagating lentivirus particles (1998-05-05),

14. 5736368 - Self assembled defective non-self propagating lentiviral particles (1998-04-07),

15. 5691170 - Generation of hybrid genes and proteins by virus-mediated recombination (1997-11-25),

Title: Innovations by Linda R. Gritz in Breast Cancer Treatment

Introduction

Linda R. Gritz is an accomplished inventor based in Somerville, Massachusetts, known for her significant contributions to cancer treatment technologies. With a remarkable portfolio of 19 patents, Gritz has been at the forefront of innovative solutions aimed at combating breast cancer and melanoma.

Latest Patents

Among her latest patents, Gritz has developed a groundbreaking system for treating and preventing breast cancer. This invention involves administering a recombinant poxvirus that contains foreign nucleic acid encoding at least one breast cancer antigen, promising new possibilities for individuals at risk or suffering from this disease. Additionally, her work on multi-antigen vectors for melanoma encompasses peptides, polypeptides, and nucleic acids that serve in diagnosing, treating, or preventing this aggressive form of cancer.

Career Highlights

Throughout her career, Gritz has made significant strides in the biotechnology field. She has worked with prominent companies such as Therion Biologics Corporation and Sanofi Pasteur Inc., where her expertise and innovative ideas became pivotal in advancing research and product development.

Collaborations

Collaborating with other talented professionals, including Dennis L. Panicali and Gail P. Mazzara, Gritz has leveraged her skills to enhance the collective knowledge and efficacy in cancer treatment strategies, showcasing the importance of teamwork in driving innovation.

Conclusion

Linda R. Gritz continues to inspire with her dedication to finding innovative solutions to pressing health challenges. Her extensive patent portfolio not only highlights her creative capabilities but also reflects her commitment to improving patient outcomes in the cancer treatment arena.

This text is generated by artificial intelligence and may not be accurate.